(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 October 2015 (15.10.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/157238 A3

(51) International Patent Classification:
A61K 8/64 (2006.01) *C07K 16/42* (2006.01)

(21) International Application Number:
PCT/US2015/024650

(22) International Filing Date:
7 April 2015 (07.04.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/976,684 8 April 2014 (08.04.2014) US

(71) Applicant: **MEDIMMUNE, LLC** [US/US]; One Medimmune Way, Gaithersburg, MD 20878 (US).

(72) Inventors: **ETTINGER, Catherine**; c/o Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). **KARNELL, Jodi**; c/o Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). **DAMS-CHRODER, Melissa**; c/o Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). **CHOWDHURY, Partha**; c/o Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). **XIAO, Xiaodong**; c/o Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). **TSUI, Ping**; c/o Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). **VARKEY, Reena**; c/o Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). **DRABIC, Stacey**; c/o Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). **CARTER, Laura**; 2687 Georgetown Blvd., Ann Arbor, MI 48105 (US). **HERBST, Ronald**; c/o Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). **DU, Qun**; c/o Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). **NAIMAN, Brian, Michael**; c/o Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US).

(74) Agents: **OYLOE, Jacob** et al.; Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: BINDING MOLECULES SPECIFIC FOR IL-21 AND USES THEREOF

FIG. 1A

VH Alignment:



VL Alignment:






FIG. 1A Contd.





(57) Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21 -mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.

WO 2015/157238 A3

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
10 December 2015